Nov 7 2024
How the “OpenAI of stem cell therapy” attracts partners without marketing
Micha Breakstone, CEO of Somite.ai, discusses how a single article in Forbes helped Somite to raise $5 million without having to chase investors, why branding Somite as a TechBio, rather than a Biotech, has helped to reduce the perceived risk for investors, and why early-stage science companies should focus their marketing efforts on specific objectives, like securing funding, attracting talent, or establishing partnerships.In this episode, you'll learn:02:13 The vision behind Somite.ai04:18 Timing and strategy for launching Somite.ai06:45 TechBio vs. Biotech: Understanding the difference08:59 Partnership models in AI and Biotech09:58 Creating a digital twin of a human embryo12:00 Communication strategies for investors14:09 Leveraging your scientific founders16:27 Navigating the biotech landscape17:58 Marketing strategies in science20:38 Operational excellence and strategy23:23 Commercialization models in TechBio23:46 Marketing advice for science startups26:03 Book recommendations for science communicatorsNotes and references:- The article from Forbes: This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market- Book recommendation: The Song of the Cell by Siddhartha MukherjeeTo connect with Micha Breakstone:- LinkedIn- Somate.aiTo connect with Joachim Eeckhout, host of the podcast:- LinkedIn- Contact form >>> Subscribe to The Science Marketer newsletter